TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15030341

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment applied once daily
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment applied twice daily
Number of subjects: 624

Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate (HA) ointment applied twice daily
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment (both once and twice daily)
Number of subjects: 624
Study: 11505807

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg daily for one month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no antihistamine)
Number of subjects: 40
Study: 9755264

Group type: EXPERIMENTAL
Intervention: DTaP vaccine (acellular pertussis component DTP vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTP vaccine (whole cell pertussis component DTP vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DT vaccine (diphtheria and tetanus toxoids vaccine)
Number of subjects: 0
Study: 8113557

Group type: EXPERIMENTAL
Intervention: Anatomic mapping approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electrogram mapping approach
Number of subjects: 50
Study: 3169112

Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS 10/170
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS 16/260
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxprenolol OROS (both systems)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30940217

Group type: EXPERIMENTAL
Intervention: Plant extract supplement (Aloe gel, grape juice, Polygonum cuspidatum)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 30047573

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ 200 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA 81 mg)
Number of subjects: 76
Study: 26169646

Group type: EXPERIMENTAL
Intervention: Suction Calibration System (SCS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bougie
Number of subjects: 26
Study: 24557326

Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Posterolateral instrumented fusion (PLF)
Number of subjects: 100
Study: 22507333

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid therapy
Number of subjects: 0
Study: 19464030

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (videoconference with school nurse and diabetes team every month)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care (medical visits every 3 months, communication as needed)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 41
Study: 17239798

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (target INR range 2.0-3.0)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Aspirin (30-325 mg daily)
Number of subjects: 1068
Study: 14872246

Group type: EXPERIMENTAL
Intervention: Head-out water immersion (HOI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Head-out water immersion (HOI) during dynamic exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control groups (non-diving housewives and non-diving young women)
Number of subjects: 18
Study: 11577619

Group type: EXPERIMENTAL
Intervention: Plausibility-enhancing manipulation (reading accounts of the occurrence of events) combined with personalized suggestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plausibility manipulation alone
Number of subjects: 0
Study: 9614159

Group type: EXPERIMENTAL
Intervention: Skim milk + bifidobacteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Skim milk alone
Number of subjects: 0
Study: 8305412

Group type: EXPERIMENTAL
Intervention: Lovastatin alone or in combination with fish oil concentrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normolipemic control subjects
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia patients
Number of subjects: 14
Study: 2846479

Group type: EXPERIMENTAL
Intervention: Neutron radiotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Photon radiotherapy
Number of subjects: 32
Study: 31815643

Group type: EXPERIMENTAL
Intervention: 5 days of antibiotic prophylaxis
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 28601506

Group type: EXPERIMENTAL
Intervention: Formal sex education
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Kegel exercises
Number of subjects: 145

Group type: COMPARATOR
Intervention: Routine postmenopausal care
Number of subjects: 145
Study: 26370445

Group type: EXPERIMENTAL
Intervention: Resting heart rate ≤65 bpm
Number of subjects: 2812

Group type: EXPERIMENTAL
Intervention: Resting heart rate >65 bpm
Number of subjects: 2812
Study: 24175487

Group type: EXPERIMENTAL
Intervention: Cannabis users
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Female cannabis users
Number of subjects: 73

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 73
Study: 22006873

Group type: EXPERIMENTAL
Intervention: Elective left colectomy for colon cancer (CC)
Number of subjects: 1721

Group type: EXPERIMENTAL
Intervention: Elective left colectomy for diverticular disease (DD)
Number of subjects: 1721
Study: 19765502

Group type: EXPERIMENTAL
Intervention: LHW+ME
Number of subjects: 1100

Group type: COMPARATOR
Intervention: ME
Number of subjects: 1100
Study: 17680654

Group type: EXPERIMENTAL
Intervention: Telaprevir alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Telaprevir + pegylated interferon-alpha-2a (PEG-IFN-alpha-2a)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PEG-IFN-alpha-2a and ribavirin after 14-day dosing period
Number of subjects: 16
Study: 15153324

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 37614

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 37614
Study: 11510709

Group type: EXPERIMENTAL
Intervention: Dalteparin 2,500 iu, subcutaneously once daily for four or five days post-operatively
Number of subjects: 76

Group type: COMPARATOR
Intervention: Saline (placebo), subcutaneously once daily for four or five days post-operatively
Number of subjects: 76
Study: 9300751

Group type: EXPERIMENTAL
Intervention: Postoperative low dose radiotherapy (5 x 2 Gy; total: 10 Gy)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Postoperative medium dose radiotherapy (5 x 3.5 Gy; total: 17.5 Gy)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (1 x 7 Gy)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Postoperative radiotherapy (5 x 3.5 Gy; total: 17.5 Gy)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of preoperative group with ipsilateral Brooker Grade III and IV ossification
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Functional failures in HOP 1
Number of subjects: 410

Group type: COMPARATOR
Intervention: Functional failures in HOP 2
Number of subjects: 410
Study: 8327418

Group type: EXPERIMENTAL
Intervention: Personalized risk invitation
Number of subjects: 2076

Group type: COMPARATOR
Intervention: General risk invitation
Number of subjects: 2076

Group type: COMPARATOR
Intervention: No risk factor questionnaire + generic invitation
Number of subjects: 2076

Group type: COMPARATOR
Intervention: No risk factor questionnaire + general risk invitation
Number of subjects: 2076

Group type: COMPARATOR
Intervention: Risk factor questionnaire + general risk invitation
Number of subjects: 2076

Group type: COMPARATOR
Intervention: Risk factor questionnaire + personal risk invitation
Number of subjects: 2076
Study: 3733491

Group type: EXPERIMENTAL
Intervention: Subliminal emotional words presented to the right visual field
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subliminal neutral words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal emotional words
Number of subjects: 0
Study: 31390891

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring data
Number of subjects: 463
Study: 28749095

Group type: EXPERIMENTAL
Intervention: Remifentanil concentration 2 ng/mL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Remifentanil concentration 6 ng/mL
Number of subjects: 30
Study: 27209482

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 24366103

Group type: EXPERIMENTAL
Intervention: Inosine (500-mg capsules taken orally up to 2 capsules 3 times per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 24030274

Group type: EXPERIMENTAL
Intervention: AAQ
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AAQ + AMX
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pre-intervention
Number of subjects: 100
Study: 20650452

Group type: EXPERIMENTAL
Intervention: EGD plus EUS
Number of subjects: 172

Group type: COMPARATOR
Intervention: EGD plus TUS
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: EGD with standard, forward‐viewing endoscope
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: EGD with oblique‐viewing echoendoscope
Number of subjects: 172
Study: 19112800

Group type: EXPERIMENTAL
Intervention: Fractional photothermolysis treatment
Number of subjects: 20
Study: 16650421

Group type: EXPERIMENTAL
Intervention: Single-dose methotrexate (MTX)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Multiple-dose methotrexate (MTX)
Number of subjects: 108
Study: 12785439

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the gluteus maximus for 1 hour a day, 6 days a week for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no extra treatment)
Number of subjects: 22
Study: 11769843

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic nephrectomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic nephrectomy
Number of subjects: 24
Study: 9174562

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily) + Pindolol (7.5 mg daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily) + Placebo
Number of subjects: 111
Study: 8230572

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal angioplasty (PTRA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Surgical reconstruction
Number of subjects: 58
Study: 3778162

Group type: EXPERIMENTAL
Intervention: 4.5-mm lateral borehole drilled into the femoral shaft
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group without boreholes
Number of subjects: 26
Study: 29782196

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Topical fluorometholone
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study: 26447668

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18134

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18134
Study: 24783198

Group type: EXPERIMENTAL
Intervention: Body weight support treadmill training (BWSTT)
Number of subjects: 0
Study: 22373729

Group type: EXPERIMENTAL
Intervention: FFC-AL (function-focused care intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FFC-education only (attention control)
Number of subjects: 0
Study: 21041914

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATV/RTV; 300/100 mg once daily)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Unboosted atazanavir (ATV; 400 mg once daily)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Unboosted atazanavir (ATV)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/RTV)
Number of subjects: 252
Study: 18489496

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 421
Study: 16808310

Group type: EXPERIMENTAL
Intervention: rHuEPO therapy (5000 IU 2 times per week s.c. for 4 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Clinical observation (no rHuEPO therapy)
Number of subjects: 22
Study: 11133641

Group type: EXPERIMENTAL
Intervention: Vital Heat plus cotton blanket
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cotton blanket
Number of subjects: 7

Group type: COMPARATOR
Intervention: Forced-air warming
Number of subjects: 7
Study: 9755009

Group type: EXPERIMENTAL
Intervention: Alternative garment and textile system
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Alternative clothing system
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clean air suits and impermeable patient drapes
Number of subjects: 66
Study: 7829283

Group type: EXPERIMENTAL
Intervention: Auditory STM
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Verbal STM
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Auditory LTM
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Verbal LTM
Number of subjects: 68
Study: 3389898

Group type: EXPERIMENTAL
Intervention: High sodium preterm formula
Number of subjects: 347

Group type: COMPARATOR
Intervention: Low sodium preterm formula
Number of subjects: 347
Study: 1473323

Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morning NPH insulin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet alone (baseline)
Number of subjects: 12
Study: 354829

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 155
Study: 31154306

Group type: EXPERIMENTAL
Intervention: m-health intervention 'SWAP IT Childcare' for 4 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study: 28512278

Group type: EXPERIMENTAL
Intervention: Porcine monolayer collagen matrix (mCM) with an envelope flap left coronally uncovered
Number of subjects: 27

Group type: COMPARATOR
Intervention: Porcine monolayer collagen matrix (mCM) with a coronally repositioned flap covered by mucosa
Number of subjects: 27
Study: 26360837

Group type: EXPERIMENTAL
Intervention: CYP2C9*1/*3 group
Number of subjects: 52

Group type: COMPARATOR
Intervention: CYP2C9*1/*1 group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CYP2D6*10
Number of subjects: 52
Study: 23426412

Group type: EXPERIMENTAL
Intervention: Retapamulin 1% applied twice daily for 5 days
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily for 5 days
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Retapamulin 1%
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 508
Study: 21339244

Group type: EXPERIMENTAL
Intervention: Tx-free procedures on low-prime, surface-coated extracorporeal circuitry (FX05, Terumo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tx-free procedures with standard uncoated circuitry (D902, Sorin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control - procedures requiring Tx on uncoated circuitry
Number of subjects: 80
Study: 19393841

Group type: EXPERIMENTAL
Intervention: 7-day buprenorphine patches (5, 10, and 20 microg/h, maximum dosage of 20 microg/h)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Prolonged-release tramadol tablets (75, 100, 150, and 200 mg, maximum dosage of 400 mg/d)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 7-day buprenorphine patches
Number of subjects: 134

Group type: COMPARATOR
Intervention: Prolonged-release tramadol tablets
Number of subjects: 134
Study: 16572288

Group type: EXPERIMENTAL
Intervention: Chondral defect scores (femoral and patellar)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Urinary CTX-II
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: BMI and osteophytes
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: MRI and biochemical measures
Number of subjects: 371
Study: 15080361

Group type: EXPERIMENTAL
Intervention: Sealant containing fluorosilicate glass (Helioseal‐F)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sealant containing methacryloyl fluoride‐methyl methacrylate copolymer (Teethmate‐F)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both groups (Helioseal‐F and Teethmate‐F)
Number of subjects: 18
Study: 11430634

Group type: EXPERIMENTAL
Intervention: Budipine 10 mg single dose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Budipine 10 mg t.i.d for 10 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Budipine 20 mg single dose
Number of subjects: 18

Group type: COMPARATOR
Intervention: Budipine 30 mg single dose
Number of subjects: 18
Study: 9623435

Group type: EXPERIMENTAL
Intervention: Bifrontal montage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fronto-central montage
Number of subjects: 0
Study: 7839462

Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial mitomycin-C (10 mg/m2 in 500 ml normal saline over 6 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial mitomycin-C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 20
Study: 3284340

Group type: EXPERIMENTAL
Intervention: norfloxacin (400 mg every 12 hours)
Number of subjects: 63

Group type: COMPARATOR
Intervention: cotrimoxazole (160/800 mg every 12 hours)
Number of subjects: 63
Study: 30578013

Group type: EXPERIMENTAL
Intervention: 1 g of intravenous (IV) amoxicillin‐clavulanate TID
Number of subjects: 78

Group type: COMPARATOR
Intervention: 50 mL of IV 0.9% NaCl TID (placebo)
Number of subjects: 78
Study: 28925502

Group type: COMPARATOR
Intervention: No-antibiotic regimen with supportive care (intravenous fluids, analgesia, and antipyretics as necessary)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 4-day course of antibiotics with supportive care
Number of subjects: 245

Group type: COMPARATOR
Intervention: No-antibiotic regimen with supportive care
Number of subjects: 245
Study: 26612447

Group type: EXPERIMENTAL
Intervention: Transnasal ultrathin endoscopy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 24220555

Group type: EXPERIMENTAL
Intervention: CO-101
Number of subjects: 367

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 367

Group type: COMPARATOR
Intervention: Gemcitabine (high hENT1 subgroup)
Number of subjects: 367
Study: 21701333

Group type: EXPERIMENTAL
Intervention: Intradermal avotermin (200 ng/100 μl/linear cm wound margin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intradermal avotermin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19114324

Group type: EXPERIMENTAL
Intervention: Somatostatin bolus infusion before ERCP followed by continuous infusion for 12 hours
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Somatostatin bolus before ERCP only
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no somatostatin treatment)
Number of subjects: 133
Study: 16490019

Group type: EXPERIMENTAL
Intervention: Sexual counseling and PGE1-intracavernous injection (ICI) therapy (SC+)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Only PGE1-intracavernous injection (ICI) therapy (SC-)
Number of subjects: 57
Study: 14555866

Group type: EXPERIMENTAL
Intervention: Early treatment with antidepressants (started within the first month after stroke)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Late treatment with antidepressants (started after 1 month)
Number of subjects: 62
Study: 11148431

Group type: EXPERIMENTAL
Intervention: Gum chewing for 1 hour after the meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Walking for 1 hour after the meal
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard breakfast
Number of subjects: 36
Study: 9623385

Group type: EXPERIMENTAL
Intervention: 22G polyurethane cannula
Number of subjects: 144

Group type: COMPARATOR
Intervention: 23G silicone cannula
Number of subjects: 144
Study: 7868799

Group type: COMPARATOR
Intervention: Radiotherapy (RT) only
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) and Chemotherapy (CT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combined treatment (RT and CT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cranial irradiation
Number of subjects: 37
Study: 3149764

Group type: EXPERIMENTAL
Intervention: Maintained nicotine cigarette
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Middle tar cigarette
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low tar cigarette
Number of subjects: 21
Study: 31596449

Group type: EXPERIMENTAL
Intervention: Vascular surgery
Number of subjects: 60703

Group type: EXPERIMENTAL
Intervention: Fractures surgery
Number of subjects: 60703

Group type: EXPERIMENTAL
Intervention: Gastrointestinal operations
Number of subjects: 60703
Study: 28857119

Group type: EXPERIMENTAL
Intervention: Multimorbidity (Charlson Comorbidity Index (CCI) score)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Higher symptom burden
Number of subjects: 381
Study: 25795339

Group type: EXPERIMENTAL
Intervention: Overnight fasting
Number of subjects: 20

Group type: COMPARATOR
Intervention: Elevated glucose condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prior cognitive effort
Number of subjects: 20
Study: 23332511

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 21296694

Group type: EXPERIMENTAL
Intervention: Speeda Vero cell rabies vaccine (Group A)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Verorab Vero cell rabies vaccine (Group B)
Number of subjects: 250
Study: 18675569

Group type: EXPERIMENTAL
Intervention: Systemic alpha-lipoic acid (ALA) 400 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ALA (400 mg) plus vitamins
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 66
Study: 16893702

Group type: EXPERIMENTAL
Intervention: Implanted cardioverter defibrillator therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 15254792

Group type: EXPERIMENTAL
Intervention: alpha-dihydroergocryptine (DEC) 101+/−39 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: levodopa 369+/−51 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: DEC
Number of subjects: 25

Group type: COMPARATOR
Intervention: levodopa
Number of subjects: 25
Study: 11766830

Group type: EXPERIMENTAL
Intervention: Subcutaneous GH (2 IU daily) for a minimum of 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for a minimum of 12 weeks
Number of subjects: 50
Study: 9415571

Group type: EXPERIMENTAL
Intervention: 2-hour infusion of OKT3
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous bolus infusion of OKT3
Number of subjects: 18